AD-118, AD-1181

Phase 1Small molecule

AAddpharma Inc.

AD-118, AD-1181 is one of 21 small molecule programs targeting Chronic Heart Failure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Heart FailureNot yet recruiting

Adult SubjectNot yet recruiting

Chronic Heart FailurePhase 1

Not yet recruiting

Adult SubjectPhase 1

Not yet recruiting

Competition

Competitive Landscape

25 competitors in Adult Subject

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

1 2

Abraxane

Bristol-Myers Squibb

Phase 1

1 3

Gemzar

Johnson & Johnson

Phase 1

1 4

Bayer Aspirin

Bayer

Phase 1

1 5

Alimta

SShawn Eagle

Phase 1

1 6

Erbitux

IImclone

Phase 1

1 7

FOLFOX

AstraZeneca

Phase 1

1 8

NALIRIFOX

TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

1 9

SNUG01

SSineuGene Therapeutics Co., Ltd.

Phase 2

1 10

Platinum Chemotherapy

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult Subject1 trial

A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects

Not yet recruiting·AAddpharma Inc.·Phase 1·NCT07476157·70 enrolled

Chronic Heart Failure1 trial

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-118 Compared to AD-1181 in Healthy Adult Volunteers

Not yet recruiting·AAddpharma Inc.·Phase 1·NCT07717749·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AD-118, AD-1181. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AD-118, AD-1181 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AD-118, AD-1181. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Addpharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAddpharma Inc.

AD-118, AD-1181

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult Subject1 trial

Chronic Heart Failure1 trial

References

Drug Info

Quick Facts

Related News